Syndax Pharmaceuticals (SNDX) Announces Proposed Public Offering of Common Stock

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.

Citigroup and Cowen are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Oklo launches new $1B at-the-market stock offering program
• ONEOK Inc (OKE) PT Raised to $93 at TD Cowen
• Zenas BioPharma (ZBIO) files for up to 7M share offering by selling stockholders